Bristol-myers Squibb Compnay

X-body, Inc.

Juno Therapeutics Gmbh

Viiv Healthcare UK (no.5) Limited

Viiv Healthcare UK (no. 4) Limited

Novartis Ag

Memorial Sloan Kettering Cancer Center

Viiv Healthcare UK Limited

Yan Chen

Nicholas A Meanwell

Paul Michael Scola

Eric L Smith

Piyasena Hewawasam

Andrew Charles Good

Sing-Yuen Sit

Alicia Regueiro-Ren

Richard W Wagner

Jie Chen

Ny Sin

Steven M Shamah

Csaba Pazmany

Ai Ching Lim

Martin C Wright

Jochem Gokemeijer

Alan S Harris

Lin Sun

Zheng Liu

Brian Lee Venables

Li-Qiang Sun

Tod M Woolf

James Aaron Balog

Jeffrey Allen Campbell

Jacob Swidorski

Michael Wittekind

Richard A Hartz

Alan Xiangdong Wang

Semih Ullah Tareen

Mark D Wittman

Satheesh Kesavan Nair

Audris Huang

Harold A Mastalerz

Andrew P Degnan

Bradley C Pearce

Bireshwar Dasgupta

Guifen Zhang

Xiangdong Alan Wang

Elena Getmanova

Jui Dutta-Simmons

Li Xu

Alexander Litovchick

Blythe D Sather

Collin Hauskins

Kimberly Harrington

Rebecca Wu

Godwin Kwame Kumi

Sunkyu Kim

Rupesh Amin

Shivang Doshi

Kristy Haas

Keming Zhang

Mariana Cota Stirner

Audrey Olshefsky

Erik Hess

Matthew D Hill

Xizhong Huang

Ira B Dicker

Aye Chen

Melissa Works

Li-Quang Sun

Ruth Salmon

Cyr De Imus

Alan Xizhong Huang

Steven Kovats

Pascale Richalet

Beata Nowicka-Sans

Stefan Ponko

Jon Jones

Erika M V Araujo

Suresh Babu Vishwa Krishna Penmetsa

Bharat Dinkar Shimpukade

Alicia Regueiro-ren

Steve Shamah

Provided herein are chimeric receptors, including chimeric antigen receptors (CARs), comprising BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof, including heavy chain variable (V) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, including a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof including in adoptive cell therapy.

Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides

Provided are ROR1 binding molecules, including anti-ROR1 antibodies, including antibody fragments such as variable heavy chain (VH) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). In some embodiments, the antibodies specifically bind to ROR1. Among the antibodies are human antibodies, including those that compete for binding to ROR1 with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.

Antibodies and chimeric antigen receptors specific for ROR1

Provided are CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). Among the antibodies are human antibodies, including those that compete for binding to CD19 with reference antibodies, such as murine antibodies. In some embodiments, the antibodies display similar functional properties to the reference antibodies, such as comparable binding affinities and/or competitive inhibition properties. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.

Antibodies and chimeric antigen receptors specific for CD19

The present invention provides antigen-binding polypeptides, including bi-specific antigen-binding polypeptides, that specifically bind to a first and a second target antigen with high affinity. The present invention also provides novel antigen-binding polypeptides that specifically bind to HER2 and antagonize HER2 activation. The invention also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen binding polypeptides. Methods of using antigen-binding polypeptide of the invention to treat disease, including cancer, are also encompassed by the invention.

Bi-specific antigen-binding polypeptides

Disclosed are compounds of Formula (I): or a salt thereof, wherein R, R, R, R, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Pyridinyl substituted oxoisoindoline compounds

Provided are methods and compositions for the production of novel antibodies that bind specifically to a target antigen. These methods and compositions are particularly useful for producing antibodies having the antigen binding specificity of a reference antibody but with improved properties (e.g., binding affinity, immunogenicity, and thermodynamic stability) relative to the reference antibody.

Antibody screening methods

Provided herein are BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof such as heavy chain variable (VH) regions and single-chain antibody fragments, and chimeric receptors comprising the anti-BCMA binding molecules such as chimeric antigen receptors (CARs). In some embodiments, the anti-BCMA antibodies or antigen-binding fragments thereof specifically bind to BCMA-1. Among the anti-BCMA antibodies are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs or BCMA-binding molecules and uses thereof such as in adoptive cell therapy.

Antibodies and chimeric antigen receptors specific for B-cell maturation antigen

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from Ccycloalkyl, Ccycloalkenyl, Cspirocycloalkyl, Cspirocycloalkenyl, Coxacycloalkyl, Cdioxacycloalkyl, Coxacycloalkenyl, Cdioxacycloalkenyl, Ccyclodialkenyl, Coxacyclodialkenyl, Coxaspirocycloalkyl and Coxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is &#x2014;Calkyl-halo. These compounds are useful for the treatment of HIV and AIDS.

Triterpenoids with HIV maturation inhibitory activity

The invention provides methods and compositions for identifying binding polypeptides (e.g., antibodies or antigen binding fragments thereof) that specifically binds to a cell-surface antigen. The methods of the invention generally comprise contacting a variegated nucleic acid-display library of binding polypeptides with a cell-surface antigen displayed on the exterior surface of a cell; and isolating from the library at least one library member that specifically binds to the cell-surface antigen on the exterior surface of the cell.

Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes

Provided are methods and compositions for identifying binding polypeptides (e.g., antibodies or antigen binding fragments thereof) that specifically binds to a cell-surface antigen. The methods of the invention generally comprise contacting a variegated nucleic acid-display library of binding polypeptides with a cell-surface antigen displayed on the exterior surface of a cell; and isolating from the library at least one library member that specifically binds to the cell-surface antigen on the exterior surface of the cell. Also provided are novel nucleic acid display libraries (e.g., DNA display libraries) useful in the methods of the invention.

Methods and compositions for generation of binding agents against cell surface antigens

The invention provides methods and compositions useful for identifying polypeptides with desired characteristics in vitro.

X-display complexes for protein screening methods

Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CH or N; Y is CR5 or N; and R1, R2, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase 1 (HPK1), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer. 

Isofuranone compounds useful as HPK1 inhibitors

The present invention provides binding polypeptides (e.g., antibodies or fragments thereof) that specifically bind to a target antigen (e.g., a human antigen, e.g., human PDGFR&#x3b2;) with high affinity. The invention also provides, libraries of binding polypeptides, pharmaceutical compositions, as well as nucleic acids encoding binding polypeptides, recombinant expression vectors and host cells for making such binding polypeptides. Methods of using binding polypeptide of the invention to diagnose and treat disease are also encompassed by the invention.

PDGF receptor beta binding polypeptides

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.

C-3 and C-17 modified triterpenoids as HIV-1 inhibitors

Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (V) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.

Growing community of inventors

Lexington, MA, United States of America

Yan Chen